Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

78.73 +1.25 (+1.62%)
Streaming Delayed Price Updated: 11:22 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 125,846
Open 78.50
Bid (Size) 78.52 (100)
Ask (Size) 78.95 (100)
Prev. Close 77.48
Today's Range 77.80 - 80.24
52wk Range 26.20 - 80.99
Shares Outstanding 56,367,802
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗
This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
From Apogee Therapeutics
Via GlobeNewswire

Performance

YTD
+3.9%
+3.9%
1 Month
+5.3%
+5.3%
3 Month
+48.0%
+48.0%
6 Month
+104.1%
+104.1%
1 Year
+60.0%
+60.0%

More News

Read More
News headline image
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate in Upcoming Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Why Apogee Therapeutics Stock Triumphed on Thursday ↗
Via The Motley Fool
Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗
Via Investor's Business Daily
News headline image
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Gold Falls 1%; ProKidney Shares Spike Higher ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Dow Dips 1%; Mustang Bio Shares Spike Higher ↗
Via Benzinga
Topics Stocks
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗
Via Investor's Business Daily
News headline image
What's going on in today's pre-market session ↗
Via Chartmill

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
What is the current price of Apogee Therapeutics, Inc. - Common Stock?
The current price of Apogee Therapeutics, Inc. - Common Stock is 78.73
When was Apogee Therapeutics, Inc. - Common Stock last traded?
The last trade of Apogee Therapeutics, Inc. - Common Stock was at 01/09/26 11:22 AM ET
What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?
The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 4.44B
How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?
Apogee Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.